Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Polyrizon (Nasdaq: PLRZ), a development stage biotech company focused on innovative intranasal hydrogels, has announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC).
The report is accessible through the SEC's website and Polyrizon's Investor Relations website. Shareholders can request free copies of the annual report by contacting the company's Investor Relations Department.
Polyrizon (Nasdaq: PLRZ), un'azienda biotech in fase di sviluppo focalizzata su idrogeli intranasali innovativi, ha annunciato il deposito del suo Rapporto Annuale sul Modulo 20-F per l'anno fiscale conclusosi il 31 dicembre 2024, presso la U.S. Securities and Exchange Commission (SEC).
Il rapporto è accessibile tramite il sito web della SEC e il sito web delle Relazioni con gli Investitori di Polyrizon. Gli azionisti possono richiedere copie gratuite del rapporto annuale contattando il Dipartimento delle Relazioni con gli Investitori dell'azienda.
Polyrizon (Nasdaq: PLRZ), una empresa biotecnológica en etapa de desarrollo centrada en hidrogeles intranasales innovadores, ha anunciado la presentación de su Informe Anual en el Formulario 20-F para el año fiscal que finalizó el 31 de diciembre de 2024, ante la Comisión de Bolsa y Valores de EE. UU. (SEC).
El informe está accesible a través del sitio web de la SEC y el sitio web de Relaciones con Inversores de Polyrizon. Los accionistas pueden solicitar copias gratuitas del informe anual contactando al Departamento de Relaciones con Inversores de la empresa.
폴리리존 (Nasdaq: PLRZ)은 혁신적인 비강 수화젤에 중점을 둔 개발 단계의 생명공학 회사로, 2024년 12월 31일에 종료된 회계 연도에 대한 20-F 양식 연례 보고서를 미국 증권 거래 위원회(SEC)에 제출했다고 발표했습니다.
보고서는 SEC 웹사이트와 폴리리존 투자자 관계 웹사이트를 통해 접근할 수 있습니다. 주주들은 회사의 투자자 관계 부서에 연락하여 연례 보고서의 무료 사본을 요청할 수 있습니다.
Polyrizon (Nasdaq: PLRZ), une entreprise biopharmaceutique en phase de développement axée sur des hydrogels intranasaux innovants, a annoncé le dépôt de son Rapport Annuel sur le Formulaire 20-F pour l'exercice fiscal clos le 31 décembre 2024, auprès de la U.S. Securities and Exchange Commission (SEC).
Le rapport est accessible via le site Web de la SEC et le site Web des Relations Investisseurs de Polyrizon. Les actionnaires peuvent demander des copies gratuites du rapport annuel en contactant le département des Relations Investisseurs de l'entreprise.
Polyrizon (Nasdaq: PLRZ), ein Biotech-Unternehmen in der Entwicklungsphase, das sich auf innovative intranasale Hydrogels konzentriert, hat die Einreichung seines Jahresberichts auf Formular 20-F für das am 31. Dezember 2024 endende Geschäftsjahr bei der U.S. Securities and Exchange Commission (SEC) bekannt gegeben.
Der Bericht ist über die Website der SEC und die Website der Investor Relations von Polyrizon zugänglich. Aktionäre können kostenlose Kopien des Jahresberichts anfordern, indem sie die Abteilung für Investor Relations des Unternehmens kontaktieren.
- None.
- None.
Raanana, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the "SEC").
The report is available on the SEC's website, at www.sec.gov and Polyrizon’s Investor Relations website, at https://investor.polyrizon-biotech.com/.
Shareholders can obtain copies of Polyrizon’s Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon’s Investor Relations Department at IR@polyrizon-biotech.com.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
Where can investors access Polyrizon's (PLRZ) 2024 Annual Report?
How can shareholders obtain a copy of Polyrizon's (PLRZ) 2024 Form 20-F?
What type of company is Polyrizon (PLRZ) and what is their main focus?
When did Polyrizon (PLRZ) file their 2024 Annual Report?
